BackgroundLong-term outcomes of drug-eluting stents (DES) versus bare-metal stents
(BMS) in patients with ST-segment elevation myocardial infarction (STEMI)
remain uncertain.ObjectiveTo investigate long-term outcomes of drug-eluting stents (DES) versus
bare-metal stents (BMS) in patients with ST-segment elevation myocardial
infarction (STEMI).MethodsWe performed search of MEDLINE, EMBASE, the Cochrane library, and ISI Web of
Science (until February 2013) for randomized trials comparing more than
12-month efficacy or safety of DES with BMS in patients with STEMI. Pooled
estimate was presented with risk ratio (RR) and its 95% confidence interval
(CI) using random-effects model.ResultsTen trials with 7,592 participants with STEMI were included. The overall
results showed that there was no significant difference in the incidence of
all-cause death and definite/probable stent thrombosis between DES and BMS
at long-term follow-up. Patients receiving DES implantation appeared to have
a lower 1-year incidence of recurrent myocardial infarction than those
receiving BMS (RR = 0.75, 95% CI 0.56 to 1.00, p= 0.05). Moreover, the risk
of target vessel revascularization (TVR) after receiving DES was
consistently lowered during long-term observation (all p< 0.01). In
subgroup analysis, the use of everolimus-eluting stents (EES) was associated
with reduced risk of stent thrombosis in STEMI patients (RR = 0.37,
p=0.02).ConclusionsDES did not increase the risk of stent thrombosis in patients with STEMI
compared with BMS. Moreover, the use of DES did lower long-term risk of
repeat revascularization and might decrease the occurrence of
reinfarction.